[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Biomaven Peter Suzman Peter Suzman posts on X about $hrow, drugs, amgn, $regn the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::111029613/interactions)  - X Week XXXXXX +364% - X Month XXXXXX +67% - X Months XXXXXXX +270% - X Year XXXXXXX +137% ### Mentions: X [#](/creator/twitter::111029613/posts_active)  - X Week XX +71% - X Month XX +65% - X Months XXX +21% - X Year XXX +111% ### Followers: XXXXX [#](/creator/twitter::111029613/followers)  - X Week XXXXX +0.12% - X Month XXXXX +0.59% - X Months XXXXX +5% - X Year XXXXX +7.70% ### CreatorRank: undefined [#](/creator/twitter::111029613/influencer_rank)  ### Social Influence [#](/creator/twitter::111029613/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [$hrow](/topic/$hrow), [drugs](/topic/drugs), [amgn](/topic/amgn), [$regn](/topic/$regn), [$amgn](/topic/$amgn), [jnj](/topic/jnj), [$jnj](/topic/$jnj), [$pcyc](/topic/$pcyc), [$qure](/topic/$qure) **Top accounts mentioned or mentioned by** [@jamesekrause](/creator/undefined) [@jsm2334](/creator/undefined) [@clarksterh](/creator/undefined) [@aaronrosenblum5](/creator/undefined) [@rockrat2](/creator/undefined) [@cremieuxrecueil](/creator/undefined) [@rcbregman](/creator/undefined) [@dobssi](/creator/undefined) [@mbeisen](/creator/undefined) [@zipjet](/creator/undefined) [@elonmusk](/creator/undefined) [@snupsnus](/creator/undefined) [@user1478](/creator/undefined) [@maverickny](/creator/undefined) [@jonesallen234](/creator/undefined) [@aamortazavi](/creator/undefined) [@mopgcw](/creator/undefined) [@eldjb1](/creator/undefined) [@worstall](/creator/undefined) [@biohazard3737](/creator/undefined) **Top assets mentioned** [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Amgen, Inc. (AMGN)](/topic/$amgn) [Johnson & Johnson (JNJ)](/topic/$jnj) ### Top Social Posts [#](/creator/twitter::111029613/posts) --- Top posts by engagements in the last XX hours "Been thinking more about the $HROW biosimilar deal. The key here is that most biosimilar marketing is payer-centric - once there are multiple players (as there are already for Lucentis) it's all been about convincing payers to chose your product in an environment of rapidly declining ASPs. But these drugs are largely in-office buy-and-bill so a prescriber-centric approach makes much more sense. Further there is significant cost-pressure from payers - indeed some dozen insurers (like BCBS Michigan) even require step-therapy starting with off-label compounded Avastin. (Medicare Advantage payers"  [@Biomaven](/creator/x/Biomaven) on [X](/post/tweet/1946223364147757370) 2025-07-18 14:59:43 UTC 8516 followers, 1526 engagements "The Eylea biosimilar space is a bit of a mess right now. $REGN formulation patent seems to expire in 2027 but they have a deal for another competitor to enter in 2026 and $AMGN is already on the market at-risk (they don't use a buffer). So likely for $HROW this will be a 2027 story but same dynamics apply as for Lucentis. So then I would see tremendous financial incentives for payers to require Eylea biosimilar step-therapy before paying for Eylea HD or Vabysmo"  [@Biomaven](/creator/x/Biomaven) on [X](/post/tweet/1946223365989306512) 2025-07-18 14:59:44 UTC 8516 followers, 1179 engagements "$QURE weakness on partnering their key asset reminds me a bit of $PCYC weakness (stock fell to low teens if I recall correctly on dashed hopes for merger) shortly after partnered ibrutinib with $JNJ The success of the drug led to them being taken out for $XXX a few years later"  [@Biomaven](/creator/x/Biomaven) on [X](/post/tweet/1317176068927856640) 2020-10-16 18:50:21 UTC 8515 followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Biomaven Peter Suzman
Peter Suzman posts on X about $hrow, drugs, amgn, $regn the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXXX +364%
- X Month XXXXXX +67%
- X Months XXXXXXX +270%
- X Year XXXXXXX +137%
Mentions: X #
- X Week XX +71%
- X Month XX +65%
- X Months XXX +21%
- X Year XXX +111%
Followers: XXXXX #
- X Week XXXXX +0.12%
- X Month XXXXX +0.59%
- X Months XXXXX +5%
- X Year XXXXX +7.70%
CreatorRank: undefined #
Social Influence #
Social category influence stocks finance
Social topic influence $hrow, drugs, amgn, $regn, $amgn, jnj, $jnj, $pcyc, $qure
Top accounts mentioned or mentioned by @jamesekrause @jsm2334 @clarksterh @aaronrosenblum5 @rockrat2 @cremieuxrecueil @rcbregman @dobssi @mbeisen @zipjet @elonmusk @snupsnus @user1478 @maverickny @jonesallen234 @aamortazavi @mopgcw @eldjb1 @worstall @biohazard3737
Top assets mentioned Regeneron Pharmaceuticals Inc (REGN) Amgen, Inc. (AMGN) Johnson & Johnson (JNJ)
Top Social Posts #
Top posts by engagements in the last XX hours
"Been thinking more about the $HROW biosimilar deal. The key here is that most biosimilar marketing is payer-centric - once there are multiple players (as there are already for Lucentis) it's all been about convincing payers to chose your product in an environment of rapidly declining ASPs. But these drugs are largely in-office buy-and-bill so a prescriber-centric approach makes much more sense. Further there is significant cost-pressure from payers - indeed some dozen insurers (like BCBS Michigan) even require step-therapy starting with off-label compounded Avastin. (Medicare Advantage payers"
@Biomaven on X 2025-07-18 14:59:43 UTC 8516 followers, 1526 engagements
"The Eylea biosimilar space is a bit of a mess right now. $REGN formulation patent seems to expire in 2027 but they have a deal for another competitor to enter in 2026 and $AMGN is already on the market at-risk (they don't use a buffer). So likely for $HROW this will be a 2027 story but same dynamics apply as for Lucentis. So then I would see tremendous financial incentives for payers to require Eylea biosimilar step-therapy before paying for Eylea HD or Vabysmo" @Biomaven on X 2025-07-18 14:59:44 UTC 8516 followers, 1179 engagements
"$QURE weakness on partnering their key asset reminds me a bit of $PCYC weakness (stock fell to low teens if I recall correctly on dashed hopes for merger) shortly after partnered ibrutinib with $JNJ The success of the drug led to them being taken out for $XXX a few years later" @Biomaven on X 2020-10-16 18:50:21 UTC 8515 followers, XX engagements